This Special Communication discusses the essential elements of designing and implementing informed consent practices for psychedelic medicine.
This Viewpoint examines how US states are reforming legislation to allow access to psychedelics for therapeutic use, but federal laws consider these agents to be Schedule I drugs, and the discordance between state and federal law may create confusion and conflict.
This Viewpoint examines the privacy concerns raised by medical uses of large language models, such as chatbots.
This Viewpoint describes medical applications of generative pretrained transformers (GPTs) and related artificial intelligence (AI) technologies and considers whether new forms of regulation are necessary to minimize safety and legal risks to patients and clinicians.
You currently have no searches saved.